8-K: Current report filing
Published on April 25, 2023
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of each exchange on which registered | ||
|
|
The Stock Market, LLC |
|||
|
|
The Stock Market, LLC |
| Item 8.01. | Other Events. |
On April 24, 2023, the Company issued a press release regarding the activation of the first Spanish site to begin accrual of patients for a Phase 1b/2 clinical trial of LB-100, the Company’s lead anti-cancer compound, added to Doxorubicin as first-line treatment of Advanced Soft Tissue Sarcoma.
| Item 9.01. | Financial Statements and Exhibits. |
(d) There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which exhibit is incorporated herein by reference.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | April 25, 2023 |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. |
|
| By: | /s/ JOHN S. KOVACH | ||
| John S. Kovach, Chief Executive Officer | |||
| 3 |
INDEX TO EXHIBITS
| Exhibit No. | Description | |
| 99.1 | Press Release regarding the activation of the first Spanish site to begin accrual of patients for a Phase 1b/2 clinical trial of LB-100, the Company’s lead anti-cancer compound, added to Doxorubicin as first-line treatment of Advanced Soft Tissue Sarcoma. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 4 |